I am a
Home I AM A Search Login

Papers of the Week

2020 Sep 06

Cochrane Database Syst Rev


Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.


Mittermeier T, Farrant C, Wise MR
Cochrane Database Syst Rev. 2020 Sep 06; 9:CD012658.
PMID: 32909630.


In the absence of treatment, endometrial hyperplasia (EH) can progress to endometrial cancer, particularly in the presence of histologic nuclear atypia. The development of EH results from exposure of the endometrium to oestrogen unopposed by progesterone. Oral progestogens have been used as treatment for EH without atypia, and in some cases of EH with atypia in women who wish to preserve fertility or who cannot tolerate surgery. EH without atypia is associated with a low risk of progression to atypia and cancer; EH with atypia is where the cells are structurally abnormal, and has a higher risk of developing cancer. Oral progestogen is not always effective at reversing the hyperplasia, can be associated with side effects, and depends on patient adherence. The levonorgestrel-intrauterine system (LNG-IUS) is an alternative method of administration of progestogen and may have some advantages over non-intrauterine progestogens.